1. Home
  2. CMC vs CELC Comparison

CMC vs CELC Comparison

Compare CMC & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Commercial Metals Company

CMC

Commercial Metals Company

HOLD

Current Price

$71.74

Market Cap

7.5B

Sector

Industrials

ML Signal

HOLD

Logo Celcuity Inc.

CELC

Celcuity Inc.

HOLD

Current Price

$139.86

Market Cap

7.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CMC
CELC
Founded
1915
2011
Country
United States
United States
Employees
N/A
155
Industry
Steel/Iron Ore
Medical Specialities
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.5B
7.0B
IPO Year
1994
2017

Fundamental Metrics

Financial Performance
Metric
CMC
CELC
Price
$71.74
$139.86
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
9
9
Target Price
$73.33
$112.56
AVG Volume (30 Days)
773.7K
1.1M
Earning Date
03-26-2026
05-13-2026
Dividend Yield
1.20%
N/A
EPS Growth
N/A
N/A
EPS
2.41
N/A
Revenue
$7,918,430,000.00
N/A
Revenue This Year
$18.81
N/A
Revenue Next Year
$6.34
$720.19
P/E Ratio
$29.34
N/A
Revenue Growth
25.57
N/A
52 Week Low
$45.50
$10.26
52 Week High
$84.87
$151.02

Technical Indicators

Market Signals
Indicator
CMC
CELC
Relative Strength Index (RSI) 57.28 59.55
Support Level $67.91 $100.58
Resistance Level $72.41 $151.02
Average True Range (ATR) 1.98 8.59
MACD -0.07 0.61
Stochastic Oscillator 71.06 70.48

Price Performance

Historical Comparison
CMC
CELC

About CMC Commercial Metals Company

Commercial Metals Co is a manufacturer and supplier of early-stage construction materials, including steel reinforcing bars, concrete pipes, precast products, and soil stabilization solutions. It also produces merchant bar, steel fence posts, and wire rod, serving domestic and some international markets in Europe and Asia. Its products are used in infrastructure and building projects such as highways, bridges, airports, and commercial and residential buildings.

About CELC Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.

Share on Social Networks: